Results 31 to 40 of about 2,386 (174)

Influence of LDL apheresis on LDL subtypes in patients with coronary heart disease and severe hyperlipoproteinemia

Journal of Lipid Research, 2000
Epidemiologic studies and in vitro experiments indicate that low density lipoprotein (LDL) subtypes differ concerning their atherogenic potential. Small, dense LDL are more atherogenic than large, buoyant LDL.
B.M. Schamberger, H.C. Geiss, M.M. Ritter, P. Schwandt, K.G. Parhofer   +4 more
doaj   +1 more source

Spectrum of cardiovascular manifestations in homozygous familial hypercholesterolemia

Journal of Marine Medical Society, 2023
Homozygous familial hypercholesterolemia (HoFH) is a rare, primarily an autosomal dominant genetic disorder that causes markedly elevated low-density lipoprotein (LDL) cholesterol levels predisposing patients to risk of developing premature ...
Nitin Bajaj, Balbir Singh, Ananthkrishnan Ramamoorthy, Arijit Kumar Ghosh   +3 more
doaj   +1 more source

Acute impact of apheresis on oxidized phospholipids in patients with familial hypercholesterolemia1

Journal of Lipid Research, 2012
We measured oxidized phospholipids (OxPL), lipoprotein (a) [Lp(a)], and lipoprotein-associated phospholipase A2 (Lp-PLA2) pre- and postapheresis in 18 patients with familial hypercholesterolemia (FH) and with low(∼10 mg/dl; range 10–11 mg/dl ...
Kiyohito Arai, Alexina Orsoni, Ziad Mallat, Alain Tedgui, Joseph L. Witztum, Eric Bruckert, Alexandros D. Tselepis, M. John Chapman, Sotirios Tsimikas   +8 more
doaj   +1 more source

Effectiveness of a Novel Low‐Density Lipoprotein Apheresis Device Rheocarna in Patients Undergoing Hemodialysis With Chronic Limb‐Threatening Ischemia: A Single‐Center Retrospective Study

Therapeutic Apheresis and Dialysis, EarlyView.
ABSTRACT Background Chronic limb‐threatening ischemia (CLTI) is a severe form of lower‐extremity artery disease characterized by distal lesions and microcirculatory impairment, limiting revascularization efficacy. Rheocarna is a direct hemoperfusion low‐density lipoprotein (LDL) adsorption device with potential rheological and anti‐inflammatory ...
Kunihiro Ishioka, Takayasu Ohtake, Kei Ohmori, Chika Shibuya, Tomoki Tsukahara, Mizuki Yamano, Yasuhiro Mochida, Machiko Oka, Kyoko Maesato, Yusuke Tsukamoto, Hidekazu Moriya, Sumi Hidaka, Shuzo Kobayashi   +12 more
wiley   +1 more source

Intensive Combination LDL-Lowering Therapy in a Patient With Homozygous Familial Hypercholesterolemia

JACC: Case Reports
We present a young boy with a diagnosis of homozygous familial hypercholesterolemia who presented with statin and ezetimibe resistance. The patient received lipoprotein apheresis at 6 years of age.
Hayato Tada, MD, Hirofumi Okada, MD, Masa-aki Kawashiri, MD, Masayuki Takamura, MD   +3 more
doaj   +1 more source

Long-Term Efficacy and Safety of Evinacumab in Patients with Homozygous Familial Hypercholesterolemia: Real-World Clinical Experience

Pharmaceuticals, 2022
Homozygous familial hypercholesterolemia (HoFH) is a rare, genetic condition characterized by markedly elevated plasma low-density lipoprotein cholesterol (LDL-C) concentrations from birth and increased risk of premature atherosclerotic cardiovascular ...
Claudia Stefanutti, Dick C. Chan, Serafina Di Giacomo, Claudia Morozzi, Gerald F. Watts   +4 more
doaj   +1 more source

Current Treatment Options in Homozygous Familial Hypercholesterolemia

Pharmaceuticals, 2022
Homozygous familial hypercholesterolemia (HoFH) is the rare form of familial hypercholesterolemia causing extremely high low-density lipoprotein cholesterol (LDL-C) levels, leading to atherosclerotic cardiovascular disease (ASCVD) in the first decades of
Meral Kayikcioglu, Lale Tokgozoglu
doaj   +1 more source

Substantially Elevated Atherosclerotic Risks in Japanese Severe Familial Hypercholesterolemia Defined by the International Atherosclerosis Society

JACC: Asia, 2021
Background: The International Atherosclerosis Society (IAS) has proposed “severe familial hypercholesterolemia” (FH) as a phenotype with the highest cardiovascular risk.
Sayaka Funabashi, MD, Yu Kataoka, MD, PhD, Mika Hori, PhD, Masatsune Ogura, MD, PhD, Yuriko Nakaoku, MD, PhD, Kunihiro Nishimura, MD, PhD, Takahito Doi, MD, PhD, Ryo Nishikawa, MD, Kosuke Tsuda, MD, Teruo Noguchi, MD, PhD, Mariko Harada-Shiba, MD, PhD   +10 more
doaj   +1 more source

In vivo CAR therapies: Turning the patient into their own CAR factory

HemaSphere, Volume 10, Issue 5, May 2026.
Abstract Over the past decade, ex vivo autologous chimeric antigen receptor (CAR)‐T‐cell therapies have reshaped the treatment of B‐cell malignancies. Despite their remarkable clinical efficacy, their application remains limited by complex manufacturing processes, demanding logistics, long turnaround times, and substantial costs. In vivo CAR approaches
François Vilcot, Carole‐Anne Brugère, Jaime Fuentealba, Roch Houot   +3 more
wiley   +1 more source

Diagnosis and Metabolic Management of Adult Refsum Disease: Guidance From the Medical and Scientific Committee of Global DARE (Defeat Adult Refsum Everywhere)

Journal of Inherited Metabolic Disease, Volume 49, Issue 3, May 2026.
ABSTRACT Adult Refsum disease (ARD; OMIM 266510) is a degenerative autosomal recessive condition typically diagnosed in adulthood. It affects visual, auditory and nervous system function. It is characterised by plasma, neuro‐ophthalmological and adipose tissue accumulation of the dietary‐derived phytanic acid (PA).
Radha Ramachandran, Raphael Buttigieg, Florian Eichler, Bart P. Leroy, Omar Mahroo, Rachel M. Huckfeldt, Sarah Firman, Eleanor Baldwin, Kristie DeMarco, Susan Kuranoff, Amena Fine, Reinhard Klingel, Sacha Ferdinandusse, Joseph G. Hacia, Ronald J. Wanders, Anthony S. Wierzbicki   +15 more
wiley   +1 more source